Re: Christopher C. Parker, Nicholas D. James, Christopher D. Brawley, et al. Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. Lancet 2018;392:2353-66 (European Urology Oncology)

At the 2018 European Society for Medical Oncology meeting, Parker et al. [1] presented results from a large randomised phase 3 trial exploring the role of primary tumour irradiation in patients with newly diagnosed metastatic prostate cancer. Some 2061 patients were randomised to receive standard treatment alone or with the addition of radiotherapy. Addition of radiotherapy in the overall population resulted in better failure-free survival without an overall survival (OS) benefit. However, for patients with a low metastatic burden according to the CHAARTED definition, radiotherapy resulted in better OS (hazard ratio 0.68, 95% confidence interval 0.52-0.90) and better progression-free survival and prostate cancer-specific survival.